Scroll Top

Antibody-drug Conjugates in Relapsed/Refractory Multiple Myeloma: from Bench to Bedside

COMY_2022_symposium logo

Independent symposium at the 8th World Congress on Controversies in Multiple Myeloma (COMy)

Publication date: 12 May 2022

Please note that only the live symposium was accredited by EACCME®

Chaired by Mohamad Mohty with Salomon Manier, Suzanne Trudel and Rakesh Popat this 1 hour 15 minute hybrid symposium focused on providing delegates with the most recent knowledge on antibody-drug conjugates (ADCs) and to help enhance their confidence in the use of these novel agents in clinical practice in order to improve the management of patients with relapsed/refractory multiple myeloma (RRMM) and achieve optimal clinical outcomes.

Learning objectives

After viewing the webcast, you will be able to:

  • Distinguish and explain the different mechanisms of action of ADCs in RRMM and their clinical implications
  • Analyze the latest clinical data available for ADCs in RRMM
  • Apply practical considerations in the management of patients with RRMM


  • Introduction: antibody-drug conjugates in hematology and cancer
  • Mechanism of action of antibody-drug conjugates in myeloma
  • Update on the latest clinical results
  • Practical considerations for patient management
  • Discussion and Q&A
  • Closing


Mohamad Mohty
Saint Antoine Hospital, University Pierre et Marie Curie, France

Mohamad Mohty is full Professor of Hematology and head of the Hematology and cellular therapy department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). Professor Mohty is also head of a translational research team at the Saint-Antoine Research Centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and hypomethylating agents. He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of acute leukemia and multiple myeloma. Professor Mohty is past-president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and serves on the board of the EBMT, and the Intergroupe Francophone du Myelome (IFM). He is also a member of the American Society of Hematology (ASH), American Society for Clinical Oncology (ASCO), American Society for Blood and Marrow Transplantation, European Hematology Association (EHA), and EBMT.

Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK. He has published more than 700 peer-reviewed articles in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals. He also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International, and as Associate Editor for Leukemia, EJH, etc.

Grants/research support, honoraria/consultation fees from: Amgen, Celgene, Takeda, Sanofi, Janssen, BMS, Adaptive Biotechnologies

Salomon Manier
Lille University Hospital, France

Salomon Manier is an Associate Professor of Hematology at Lille University Hospital (France), where he also worked as an instructor in Medical Oncology (2015–2019) and in Hematology (2017-2019).

Dr Manier is member of the American Society of Hematology (ASH), European Hematology Association (EHA), International Myeloma Society (IMS), Société Française d’Hématologie (SFH), and board member of Intergroupe Francophone du Myelome (IFM). He is also part of the scientific committees of ASH on Plasma Cell Neoplasia and of the American Association for Cancer Research (AACR) in myeloma. Among his invited presentations, he has contributed to the educational sessions of ASH 2017 (chairman of a session), and EHA 2020 (myeloma section).

Dr Manier has also worked as co-editor of the international journal Current Research in Translational Medicine and is an ad-hoc reviewer in the journals Blood, Leukemia, and Blood Advances. Throughout his career, Dr Manier has received a number of awards, including IMS Travel Award (2017), EHA Travel Grant (2017), TRTH EHA/ASH Translational Research Training in Hematology (2018) Force Hemato Award (2019).

Dr Manier completed his MD in 2008 at University of Paris (France) and obtained his PhD in 2017 at University of Lille (France).

Grants/research support from: Celgene, Janssen

Suzanne Trudel
Princess Margaret Cancer Centre, Toronto, Canada

Suzanne Trudel is Associate Professor in the Department of Medicine at the University of Toronto, and Attending Physician at Princess Margaret Cancer Centre, Toronto, Canada. She is also a Clinician Scientist at the Ontario Cancer Institute, Canada.

Dr Trudel received her medical degree from the University of Toronto. Her training included postdoctoral fellowships at the University of Toronto and Weill Medical College at Cornell University. She holds certifications in hematology and internal medicine from the American Board of Internal Medicine as well as the Royal College of Physicians and Surgeons of Canada. Dr Trudel’s research is focused in the areas of molecular target identification and validation and development of novel biologically based therapies for multiple myeloma.

Grants from: Janssen, GlaxoSmithKline, BMS, Genentech, Amgen, Pfizer
Honoraria fees from: Janssen, Amgen, Celgene, Karyopharm, Takeda, Sanofi
Consultation fees from: BMS, Amgen Canada, GlaxoSmithKline

University College London Hospitals NHS Foundation Trust, London, UK

Dr Rakesh Popat is Associate Professor at University College London and Consultant Hematologist at University College London Hospitals with an interest in multiple myeloma.

He graduated from Guy’s and St. Thomas’ Medical School in London and trained in hematology at St. Bartholomew’s and the Royal London Hospitals. During this time he completed a PhD in novel treatments for myeloma and was awarded a fellowship to attend the Dana Farber Cancer Institute, Boston, USA.

He is particularly experienced in novel treatments including immunotherapies such as CAR-T cell therapy and new antibody approaches. At University College Hospital, he leads the myeloma clinical trials program and is the cancer lead for early phase clinical trials at the NIHR UCLH Clinical Research Facility.

Dr Popat is the Chair of the UK Myeloma Research Alliance, NCRI Myeloma working group, is on the executive board of the UK Myeloma Forum, and the young board of the European Myeloma Network. He is the Chief Investigator for a number of relapsed myeloma studies and the Principal Investigator for the NIHR Health Informatics Collaborative Myeloma Theme.


Research funds, honoraria, consultation fees from: GSK; Honoraria fees, consultation fees from: Janssen; Consultation fees from: BMS; Honoraria fees from: Abbvie


This program is targeted at Hematologists, oncologists, oncology nurses, and all other HCPs managing RRMM.

Educational grant

Independent symposium organized by Springer Healthcare IME. This educational activity is supported by an educational grant from GlaxoSmithKline which is intended for healthcare professionals outside of the United States.

healthcare professionals completing our programs
educational programs launched
countries receiving live education


James Hutton

Senior Project Director

Related Programs |view all programs